201 related articles for article (PubMed ID: 23617353)
21. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
[TBL] [Abstract][Full Text] [Related]
22. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
Dikopf A; Wood K; Salgia R
Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
[TBL] [Abstract][Full Text] [Related]
23. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
Gautschi O; Schefer H; Riklin C; Strobel K; Diebold J
Onkologie; 2013; 36(6):342-7. PubMed ID: 23774148
[TBL] [Abstract][Full Text] [Related]
24. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.
Mirshahidi HR; Mirshahidi S
Expert Rev Anticancer Ther; 2015 Apr; 15(4):375-85. PubMed ID: 25797684
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
27. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P
J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib in the treatment of non-small-cell lung cancer.
Forde PM; Rudin CM
Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
[TBL] [Abstract][Full Text] [Related]
29. Crizotinib and testing for ALK.
Shaw AT; Solomon B; Kenudson MM
J Natl Compr Canc Netw; 2011 Dec; 9(12):1335-41. PubMed ID: 22157554
[TBL] [Abstract][Full Text] [Related]
30. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
32. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Girard N; Audigier-Valette C; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlési F
Expert Rev Anticancer Ther; 2015 Feb; 15(2):225-33. PubMed ID: 25413260
[TBL] [Abstract][Full Text] [Related]
33. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
[No Abstract] [Full Text] [Related]
34. Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study.
Zwaenepoel K; Merkle D; Cabillic F; Berg E; Belaud-Rotureau MA; Grazioli V; Herelle O; Hummel M; Le Calve M; Lenze D; Mende S; Pauwels P; Quilichini B; Repetti E
Exp Mol Pathol; 2015 Feb; 98(1):113-8. PubMed ID: 25576649
[TBL] [Abstract][Full Text] [Related]
35. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
37. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib resistance: implications for therapeutic strategies.
Dagogo-Jack I; Shaw AT
Ann Oncol; 2016 Sep; 27 Suppl 3(Suppl 3):iii42-iii50. PubMed ID: 27573756
[TBL] [Abstract][Full Text] [Related]
40. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Kaneda H; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
